C
Courtney Crim
Researcher at Research Triangle Park
Publications - 130
Citations - 8687
Courtney Crim is an academic researcher from Research Triangle Park. The author has contributed to research in topics: COPD & Fluticasone propionate. The author has an hindex of 40, co-authored 126 publications receiving 7622 citations. Previous affiliations of Courtney Crim include University of North Carolina at Chapel Hill & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Changes in forced expiratory volume in 1 second over time in copd
Jørgen Vestbo,Jørgen Vestbo,Lisa D. Edwards,Paul D. Scanlon,Julie C. Yates,Alvar Agusti,Per Bakke,Peter M.A. Calverley,Bartolome R. Celli,Harvey O. Coxson,Courtney Crim,David A. Lomas,William MacNee,Bruce E. Miller,Edwin K. Silverman,Ruth Tal-Singer,Emiel F.M. Wouters,Stephen I. Rennard +17 more
TL;DR: The rate of change in FEV(1) among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator reversibility, and patients with emphysema.
Journal ArticleDOI
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.
Alvar Agusti,Lisa D. Edwards,Stephen I. Rennard,William MacNee,Ruth Tal-Singer,Bruce E. Miller,Jørgen Vestbo,Jørgen Vestbo,David A. Lomas,Peter M.A. Calverley,Emiel F.M. Wouters,Courtney Crim,Julie C. Yates,Edwin K. Silverman,Harvey O. Coxson,Per Bakke,Ruth J. Mayer,Bartolome R. Celli +17 more
TL;DR: Overall, the results identify a novel systemic inflammatory COPD phenotype that may be the target of specific research and treatment and show associations but do not prove causality.
Journal ArticleDOI
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE).
Jørgen Vestbo,W. H. Anderson,Harvey O. Coxson,Courtney Crim,F Dawber,Lisa D. Edwards,G Hagan,Katharine Knobil,David A. Lomas,William MacNee,Edwin K. Silverman,Ruth Tal-Singer,Eclipse Investigators +12 more
TL;DR: Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points is the largest study attempting to better describe the subtypes of chronic obstructive pulmonary disease, as well as defining predictive markers of its progression.
Journal ArticleDOI
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Courtney Crim,Peter M.A. Calverley,Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Lisa R. Willits,Julie C. Yates,Jørgen Vestbo +9 more
TL;DR: Despite the benefits of ICS-containing regimens in COPD management, healthcare providers should remain vigilant regarding the possible development of pneumonia as a complication in patients receiving such therapies.
Journal ArticleDOI
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial
Jørgen Vestbo,Julie A. Anderson,Robert D. Brook,Peter M.A. Calverley,Bartolome R. Celli,Courtney Crim,Fernando J. Martinez,Fernando J. Martinez,Julie C. Yates,David E. Newby +9 more
TL;DR: All-cause mortality was unaffected by combination therapy and secondary outcomes were on-treatment rate of decline in forced expiratory volume in 1 s (FEV1) and a composite of cardiovascular events, and therefore secondary outcomes should be interpreted with caution.